Related Experiment Video
Updated: Jul 30, 2025
08:35
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
2.4K
MINOCA and INOCA: Role in Heart Failure
1Cardiology, Heart and Vessels Department, University Hospital Santa Maria, Faculty of Medicine of Lisbon University, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal. anagalmeida@gmail.com.
Current Heart Failure Reports
|May 17, 2023
Summary
Myocardial infarction (MINOCA) and ischemia (INOCA) with non-obstructive coronary disease are linked to heart failure (HF). Further research is needed for risk factors, diagnosis, and prevention strategies for MINOCA and INOCA related HF.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Heart Failure Research
Background:
- Myocardial infarction (MINOCA) and ischemia (INOCA) with non-obstructive coronary disease are emerging presentations of coronary syndromes.
- These conditions are increasingly recognized due to advancements in cardiovascular imaging.
- Both MINOCA and INOCA are associated with heart failure (HF).
Purpose of the Study:
- To review the relationship between MINOCA, INOCA, and heart failure.
- To highlight the impact of microvascular dysfunction in INOCA and HFpEF.
- To identify gaps in understanding and management of HF in MINOCA and INOCA.
Main Methods:
- Review of recent clinical literature and imaging techniques.
- Analysis of the association between MINOCA/INOCA and heart failure.
- Examination of underlying mechanisms including left ventricular dysfunction and endothelial dysfunction.
Main Results:
- MINOCA is associated with significant adverse outcomes, including prevalent heart failure events.
- INOCA, particularly involving microvascular dysfunction, is linked to heart failure with preserved ejection fraction (HFpEF).
- HF is a common complication in both MINOCA and INOCA.
Conclusions:
- MINOCA and INOCA are significantly related to heart failure, necessitating further investigation.
- Established secondary prevention strategies for HF in MINOCA are lacking.
- Coronary microvascular dysfunction in INOCA contributes to diastolic dysfunction and HFpEF.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
17
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
17
01:26Heart Failure Drugs: Inotropic Agents
645
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
472
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:27Heart Failure I: Introduction
26
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
26